| HOME >> BIOLOGY >> TECHNOLOGY |
ENDOSURGERY 28 13 15
NEUROMODULATION 17 16 1
DIVESTED BUSINESSES (103) (105) 2
WORLDWIDE $(40) $(139) $99
An explanation of the Company's use of these non-GAAP measures is provided
at the end of this document.
BOSTON SCIENTIFIC CORPORATION
ESTIMATED NON-GAAP NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
Q2 2008 Estimate Q2 2008 Estimate
(Low) (High)
GAAP results $0.04 $0.09
Estimated acquisition-related charges 0.01 0.01
Estimated restructuring-related charges 0.02 0.02
Estimated amortization expense 0.07 0.07
Adjusted results $0.14 $0.19
An explanation of the Company's use of these non-GAAP measures is provided
at the end of this document.
Use of Non-GAAP Financial Measures
To supplement Boston Scientific's condensed consolidated financial
statements presented on a GAAP basis; the Company discloses certain non-
GAAP measures that exclude certain amounts, including non-GAAP net income,
non-GAAP net income per diluted share, and regional and divisional revenue
growth rates that exclude the impact of foreign exchange. These non-GAAP
measures are not in accordance with, or an alternative for, generally
accepted accounting principles in the United States.
The GAAP measure most comparable to non-GAAP net income is GAAP net income
and the GAAP measure m
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |